Extended Data Fig. 8: PFS according to blood TMB. | Nature Medicine

Extended Data Fig. 8: PFS according to blood TMB.

From: An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Extended Data Fig. 8

TMB ≤ 16 mutations/Mb was associated with shorter PFS when combining the arms irrespective of treatment (HR 1.60 [1.05; 2.42]) Logrank test, p = 0.0025. Analysis performed: Kaplan Meier analysis according to the TMB at baseline and Cox model for HR. HR, hazard ratio; PFS, progression-free survival; TMB, tumor mutational burden.

Back to article page